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Abstract: Detailed analysis has been performed over many years of a geographic and 
temporal cohort of cats naturally infected with feline leukemia virus (FeLV). Molecular 
analysis of FeLV present in the diseased tissues and application of those viruses to 
experimental systems has revealed unique isolates with distinctive disease potential, 
previously uncharacterized virus-receptor interactions, information about the role of 
recombinant viruses in disease induction, and novel viral and cellular oncogenes implicated 
in pathogenesis, among other findings. The studies have contributed to an understanding of 
the selective forces that lead to predominance of distinctive FeLV isolates and disease 
outcomes in a natural population. 
Keywords: feline leukemia virus; lymphoma; pathogenesis; oncogenesis; long terminal 
repeat; surface glycoprotein 
 
1. Introduction 
Feline leukemia virus (FeLV) is a horizontally-transmissible, naturally occurring retrovirus of the 
domestic cat, associated with proliferative, degenerative and malignant diseases of myeloid, erythroid, 
and lymphoid origin in the natural host. This complex disease spectrum is thought to reflect a 
prolonged interaction in vivo between two genetically heterogeneous populations, i.e., FeLV itself and 
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its naturally outbreeding host. As a simple gammaretrovirus, FeLV encodes only those genes required 
for its structure and replication and carries no genetic information to which its disease potential can be 
directly attributed (Figure 1). In contrast to the relative simplicity of its genome, FeLV occurs in nature 
not as a single genetic species but as a complex family of closely related viruses. Genetic variation is 
generated during FeLV replication in vivo through error-prone reverse transcription and by 
recombination with endogenous FeLV-related sequences in the cat genome. The consequence of this 
variation is a genetically diverse virus population that is continuously shaped by selective pressures 
in vivo and from which variants arise as predominant species [1–3]. The nature of these variants, their 
relationship to disease outcome, particularly malignant disease, and the selective mechanisms leading 
to their predominance have been topics of research focus in our laboratory for many years. The 
malignant disease most frequently associated with FeLV infection is a lymphoma characterized by the 
presence of discrete tumors and diffuse infiltration of organs by lymphoid tumor cells. Three forms of 
lymphoma have been described clinically in the FeLV-infected cat: (1) thymic, a rapidly progressive 
tumor of the anterior mediastinum comprised of T-lineage cells at varying stages of developmental 
maturity, (2) alimentary, in which the tumor involves the gastrointestinal tract, and (3) multicentric, in 
which the tumor involves many organs but typically excludes the thymus [4]. Our research goal has 
been to dissect the complex, multistep cascade of events that leads to lymphoma in FeLV-infected cats, 
and thereby identify the role of viral determinants.  
Figure 1. Diagrammatic representation of integrated feline leukemia virus (FeLV) proviral 
DNA. After reverse transcription of viral RNA, the double-stranded DNA provirus is 
integrated into the host genome as shown. Indicated are the viral genes (gag, pol, and env) 
and long terminal repeat (LTR). 
 
 
Insight into the interplay between FeLV and its host was afforded by the extraordinary opportunity 
to examine diseased tissues from a cohort of naturally infected cats, the generous gift of Drs. Murray 
Gardner and James W. Casey. A rare trove of clinical material, the cohort included tissues from   
66 animals collected essentially by a single veterinary practice in Pasadena, California over a period of 
six years. Thus, the cohort represented a geographical and temporal cluster presumably exposed to a 
similar spectrum of horizontally transmissible FeLV. The cohort included twelve cases of multicentric 
lymphoma, four cases of thymic lymphoma, two cases of myeloproliferative disease, one case of mast 
cell leukemia, two cases of anemia, and two asymptomatic cases in FeLV-infected, healthy animals. 
The thymic lymphomas were demonstrated to be of T-cell origin as evidenced by clonal rearrangement 
of the T-cell receptor beta (TCRβ) locus, but the cell type of origin of the multicentric lymphomas 
could not be clearly determined. As both TCRβ and immunoglobulin heavy chain (IgH) loci were Viruses 2011, 3                  
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observed in germline configuration in those tumors [5], we have referred to them as non-B-cell 
non-T-cell multicentric lymphomas. The designation is tentative, in that no intact tissues were 
available for immunohistochemical or other analyses. Our studies of lymphomas and other diseased 
tissues in the cohort have shown that FeLV-induced malignancy is a multistep process that involves 
determinants encoded both by the virus and the host. The malignant potential of FeLV, like the closely 
related murine leukemia viruses [6], was shown to depend on at least three genetic determinants: 
(1)  transcriptional regulatory sequences in the virus long terminal repeat (LTR), (2) potential 
influences on target cell tropism and spread in vivo by variation in the envelope surface glycoprotein 
(SU), and (3) the activation of cellular oncogenes, typically by the adjacent integration of a 
transcriptionally active provirus (Figure 2). Described below are investigations of the role(s) of these 
determinants in the pathogenesis of FeLV-positive thymic and multicentric lymphomas in the natural 
cohort. The results shed light on selective pressures operative in natural FeLV infection that led to the 
predominance of viral variants, many of which have significant consequences for infection and disease 
outcome. The results have further associated a clearly distinguishable set of genetic events with 
lymphomas of each type. 
Figure 2. Schematic representation of the pathogenic determinants of FeLV. Transcriptional 
promoter and enhancer elements in the U3 region of the viral LTR bind transcription 
factors (TF) to drive expression of viral genes. Host genes near the site of integration may 
be similarly affected. If the adjacent host gene is an oncogene, activation of its expression 
can lead to malignant change. LTR variants, produced by error-prone replication, are 
associated with distinct disease outcomes through the engagement of distinct sets of 
generalized or cell type-specific transcription factors. Variation in the surface glycoprotein 
(SU) affects receptor selection and binding affinity, and can thereby influence the rate of 
virus spread, tissue tropism and disease spectrum.  
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2. The FeLV Long Terminal Repeat (LTR) as a Determinant of Pathogenesis in the Cohort 
Gene expression in retroviruses is directed by the LTR, a structure generated at the termini of the 
proviral genome by reverse transcription. The LTR is a modular structure consisting of a DNA form of 
the U3, R, and U5 regions of viral RNA (Figure 3A). The U3 is particularly relevant for the regulation 
of gene expression as it contains the transcriptional promoter and potent enhancer sequences. These 
regulatory elements can act both on adjacent viral genes and on cellular genes near the site of proviral 
integration, or indeed across significant sequence distance. As such, the LTR of FeLV is capable of 
directing a high level of viral gene expression and can also direct expression of host genes. When such 
host genes have oncogenic potential, the LTR-mediated activation plays a principal role in the 
malignant process [6]. 
Figure 3. Structure of FeLV LTR and its natural variants. (A) FeLV LTR structure as 
observed typically in asymptomatic infections in nature. The LTR contains a single 
transcriptional enhancer and promoter element as shown. Indicated are transcription factors 
that bind their cognate sites within those elements. (B) FeLV LTR structure observed in 
thymic lymphomas or in non-T-cell diseases from the natural cohort. In thymic 
lymphomas, LTRs frequently contain a duplicated enhancer with repeat lengths varying 
from 39–77 base pairs (bp). In non-T cell diseases, LTRs frequently contain a single copy 
of enhancer followed downstream by a 21-bp sequence triplicated in tandem.  
 
 
The FeLV LTR represents a region of remarkable genetic variation among natural isolates, and 
LTR variants have been linked to particular disease outcome [7–11]. LTR sequence variation and 
function were examined in diseased tissues of 21 cats in our collection (Figure 3B). In thymic 
lymphomas in the cohort, LTRs were found uniformly to contain duplications of enhancer sequences 
with repeat lengths varying from 39 to 77 base pairs (bp). Termini of the enhancer repeat units varied 
among isolates, although the LVb/Ets and Core binding sites were uniformly conserved within the 
repeat units regardless of length. Unexpectedly, functional assays using luciferase reporter genes 
driven by the LTRs demonstrated that the enhancer duplication offered little transcriptional advantage, Viruses 2011, 3                  
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and that the more complete repeat unit conferred no advantage over a shorter one [12]. Working 
together with Dr. Jack Lenz, one of the thymic lymphoma-derived FeLV LTRs was further examined 
by substitution into the potent T-lymphomagenic murine leukemia virus, SL3-3 MuLV, to generate a 
murine-feline recombinant virus. When inoculated into mice, the recombinant virus induced T-cell 
lymphoma nearly as quickly as the parent murine leukemia virus. We interpreted this finding as 
confirmation that the thymic lymphoma-derived FeLV LTR contains a potent genetic determinant of 
T-cell lymphomagenesis. We infer that the LTR is presumably adapted, through the conservation of 
key binding sites, to be recognized by transcription factors present in T cells of cats in the relevant 
target tissues for malignant change [13].  
In non-T-cell diseases in the cohort, by contrast, the predominant LTR structure contained a unique, 
previously unidentified sequence motif. Originally described from a non-T-cell, non-B-cell 
multicentric lymphoma, the LTR was shown to contain a single copy of the canonical enhancer 
followed 25-bp downstream by a 21-bp sequence triplicated in tandem [14]. PCR amplification of 
LTRs from all non-T-cell diseases in the cohort demonstrated the triplication-containing LTR in 7 of 
12 multicentric lymphomas and in all cases of myeloproliferative disease and anemia. Unlike the 
enhancer duplications in LTRs from thymic lymphomas, whose repeat length and termini were 
variable, the sequence and position of the 21-bp repeat element was precisely conserved in the LTRs 
from all tissues in which it was identified. The FeLV isolate bearing the triplication-containing LTR 
was designated FeLV-945 [5,12]. Functional analysis using reporter gene constructs demonstrated that 
the 21-bp triplication provides transcriptional enhancer function to the FeLV-945 LTR, and that it acts 
preferentially in a cell-type-specific manner [15]. These results predicted that the FeLV-945 LTR 
would confer a replicative advantage on the virus that contains it, and that such an advantage might 
account for the precise conservation and selection of the unique LTR sequence in the cohort. A test of 
this prediction was performed using recombinant, infectious FeLVs isogenic other than the LTR 
structure. These studies demonstrated that the FeLV-945 LTR confers a significant replicative 
advantage to the virus, especially in multipotential hematopoietic cells and in feline T-cells [16]. 
Others have determined that a mutation which affords as little as 1% replication advantage will 
represent 50% of the virus population within 400 replication cycles, assuming a mutation rate of 
10
−4 [17]. Thus, a replicative advantage conferred by the FeLV-945 LTR may indeed have contributed 
to predominance of the unusual isolate in the cohort. In fact, LTRs from non-T-cell diseases in the 
cohort demonstrated the 21-bp repeat element in 1, 2, 3, or 4 copies, but the triplicated form as 
represented in FeLV-945 was observed to confer the optimal replicative advantage, perhaps explaining 
its predominance [12]. 
Two possible mechanisms of action have been examined to explain the function of the 21-bp 
triplication in the context of the FeLV-945 LTR. First, we considered that the 21-bp triplication might 
function to maintain the appropriate spacing in the LTR between the enhancer and the promoter. A 
spacer function of this kind might be particularly important in an LTR, like the triplication-containing 
LTR, in which the enhancer is not tandemly repeated. This possibility was discounted, however, by 
experiments in which two copies of the triplicated 21-bp sequence in the FeLV-945 LTR were 
replaced with 42-bp of random sequence. Modification of the LTR in this way was shown to greatly 
diminish the replicative capacity of the virus, although the spacing of regulatory elements within the 
LTR was maintained. We inferred from these findings that the 21-bp triplication does not perform Viruses 2011, 3                  
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solely a spacer function but that the sequence itself is important [16]. A second possibility was then 
considered, i.e., that the 21-bp triplication contributes authentic enhancer function through the binding 
of nuclear transcription factors. In support of this possibility, it is noteworthy that the 42-bp 
contributed by two additional copies of the 21-bp repeat in the LTR represent an exact multiple of 
10.5 bp per helical turn of DNA, i.e., four whole turns [18,19]. Thus, nuclear protein binding sites 
encoded within the sequence would occur on the same face of the DNA molecule. Indeed, 
electrophoretic mobility shift assays (EMSA) using the 21-bp triplication as a probe demonstrated the 
formation of a specific protein-DNA complex using nuclear extracts prepared from cells in which the 
FeLV-945 LTR is preferentially active [16]. Sequence analysis indicated potential binding sites for the 
transcription factor, c-Myb, across the repeat junctions of the 21-bp triplication, a noteworthy finding 
in that such sites would not occur in the absence of the repeat; thus, a requirement for c-Myb binding 
to the repeat junctions of the triplication could represent the selective pressure to conserve its sequence 
precisely. Functional analysis demonstrated the specific binding of c-Myb to the triplication, and 
showed that the triplication-containing LTR is responsive to c-Myb in a manner that requires the 
presence of both c-Myb binding sites. Results further indicated that c-Myb in complex with the 21-bp 
triplication recruits the transcriptional co-activator, CREB-binding protein (CBP), to a DNA-protein 
complex assembled on the FeLV-945 LTR. In keeping with these results, FeLV-945 replication was 
shown to be positively responsive to CBP overexpression. Considering that CBP is present in 
hematopoietic cells in limiting amounts, and that the expression of CBP-responsive genes is regulated 
via competition for the limited availability of the transcriptional co-activator, we hypothesized that 
FeLV-945 replication in bone marrow may influence CBP availability and thereby alter the regulation 
of CBP-responsive genes known to be involved in normal hematopoiesis [20]. 
While the study of FeLV pathogenesis in vivo in the natural host offers the potential for key 
mechanistic insights, manipulation of the cat model experimentally is hampered by several difficulties 
including the relative unpredictability of the outcome and the prolonged latency to malignant disease. 
With this in mind, we embarked on a study of the influence of the FeLV-945 LTR in vivo through the 
construction of a recombinant murine-feline retrovirus such that pathogenesis could be studied in the 
laboratory mouse. In collaboration with Dr. Hung Fan and colleagues, a recombinant virus, termed 
MoFe2-MuLV (MoFe2), was constructed in which the U3 region of the Moloney murine leukemia 
virus (Mo-MuLV) LTR was replaced with that of the triplication-containing FeLV-945 LTR 
(Figure 4). Mo-MuLV is a gammaretrovirus that uniformly induces T-cell lymphoma of the thymus 
with a relatively short latency of 3–4 months. The tumors induced by MoFe2 were exclusively thymic 
and of T-cell origin as evidenced by clonal, somatic rearrangement of the TCRβ locus in tumor DNA 
and a surface phenotype typical of immature and maturing thymocytes. These findings demonstrated 
that the presence of the FeLV-945 LTR was unable to re-direct disease spectrum of Mo-MuLV from 
T-cell lymphoma to non-T-cell disease associated with FeLV-945 in nature [21]. The results are 
consistent with studies demonstrating a replicative advantage conferred by the FeLV-945 LTR in 
feline T-cell lines [16], and with studies described below that implicate the FeLV-945 surface 
glycoprotein, but not the LTR, as the determinant of disease spectrum. As described below, the 
induction of T-cell lymphoma by MoFe2 proved to be a rich source for the identification of potential 
oncogenes, an indication that the unique MoFe2 LTR engaged a novel set of host genes in the induction 
of lymphoma. Viruses 2011, 3                  
 
 
1687
Figure 4. Schematic representation depicting the generation of the MoFe2-MuLV viral 
mutant. Represented are the proviral DNAs of Moloney murine leukemia virus 
(MoMuLV), FeLV-945, and the recombinant virus, MoFe2-MuLV (MoFe2). Indicated 
within the U3 region of each LTR are the number of enhancer repeats (blue boxes), the 
21-bp sequence triplication (green boxes), and the transcriptional promoter (red box). The 
duplicated enhancer and promoter of MoMuLV were replaced by the corresponding 
sequence of FeLV-945 to generate the MoFe2 construct as shown.  
 
3. Viral Surface Glycoprotein (SU) as a Determinant of Pathogenesis in the Cohort 
Two proteins, the surface glycoprotein (SU) and the transmembrane protein (TM), are generated 
from the envelope gene of gammaretroviruses. SU resides on the particle surface, anchored to the TM 
protein, and is thereby positioned to make contact with the host cell surface and to interact directly 
with the receptor. The SU protein of gammaretroviruses contains three highly variable, functional 
domains required for receptor interaction and entry (Figure 5). Variable region A (VRA) is the primary 
determinant of receptor binding, and thus of host range, for FeLV and related retroviruses while 
variable region B (VRB) is a secondary determinant required for efficient infection [22–28]. An 
adjacent proline-rich region (PRR) mediates conformational changes required for virus entry [29]. 
These motifs comprise what has been termed the receptor binding domain (RBD). Outside of the 
conventionally defined RBD, additional binding determinants have been identified throughout the SU 
protein [24,30,31]. Entry of FeLV occurs after binding of the RBD to the host cell receptor, followed 
by conformational changes that ultimately lead to fusion of the viral and cellular envelopes. Thus, the 
SU protein acts as the initial determinant of tissue tropism, and the affinity of its interaction with host 
cell receptor may influence the rate of virus spread during infection.  
Four subgroups of FeLV, namely FeLV-A, -B, -C, and -T, have been identified based on SU 
sequence and receptor utilization, and each subgroup has been associated with distinct pathogenesis 
[2,32–34]. Specifically, FeLV-A viruses represent the naturally occurring, horizontally transmissible 
subgroup spread cat-to-cat in nature. These viruses are weakly pathogenic, but can result in neoplastic 
disease, typically thymic lymphoma of T-cell origin, after a protracted asymptomatic phase. FeLV-B, 
C and T are thought not to be horizontally transmissible in nature, but arise de novo within the infected 
animal by mutation of FeLV-A and/or by recombination between FeLV-A and endogenous 
FeLV-related elements in the cat genome. The disease association of FeLV-B is not clearly 
understood, but FeLV-B infection is overrepresented in tissues from lymphoma relative to Viruses 2011, 3                  
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asymptomatic infected cats or other disease conditions. Infection with FeLV-C or FeLV-T is 
associated with anemia or immunodeficiency disease, respectively [1,2]. The receptors for each 
subgroup have been identified as multiple membrane-spanning proteins that function normally as 
transporters of small molecules. FeLV-A exhibits an ecotropic host range and utilizes a thiamine 
transporter, FeTHTR1, as receptor. FeLV-B and -C exhibit a broad host range, but utilize different 
receptors for entry. FeLV-B can use the phosphate transporters FePiT1 or FePiT2 as receptor, while 
FeLV-C uses a heme transporter, FLVCR. FeLV-T binds to FePiT1 as receptor, but is unique among 
the FeLVs because it requires a co-factor termed FELIX for entry into target cells [35,36]. Sequence 
analysis of SU proteins encoded by proviruses from diseased tissues in the cohort indicated that they 
were members of FeLV subgroup A, but that they were considerably more closely related to each other 
than to other FeLV-A SU proteins examined [5,37]. This finding was unexpected since the previously 
identified members of FeLV-A exhibit strong sequence conservation (~97% amino acid sequence 
identity across SU) despite having been isolated over more than a decade from distant geographic 
locations across the world [2,3,38]. The largest sequence divergence between the cohort isolates and 
other FeLV-A SU proteins is located within the functional domains of the SU protein [37]. 
Specifically, the FeLV-945 SU protein was shown to be 89%, 73%, and 85% identical in predicted 
amino acid sequence to prototype FeLV-A/61E SU across VRA, VRB and PRR, respectively. In 
contrast, the segments of FeLV-945 SU between variable regions were 94% identical to FeLV-A/61E, 
and the 197 residues of the predicted TM product were 97% identical to FeLV-A/61E. In spite of the 
sequence differences, functional assays of receptor utilization including host range and superinfection 
interference confirmed the cohort viruses to be members of the FeLV-A subgroup [37]. Considering 
the assignment of cohort viruses to FeLV-A, the previous association of FeLV-B subtype viruses with 
T-cell lymphoma, and the predominance in the cohort of non-T-cell disease, a study was undertaken to 
determine to what extent viruses belonging to FeLV-B may contribute to the distinctive disease 
spectrum seen in the cohort [39]. The presence of FeLV-B in the genomic DNA of diseased tissues 
was examined by Southern blot analysis and PCR. FeLV-B was demonstrated in 50% of thymic 
lymphomas (2 of 4), a frequency comparable to that reported previously by us and others [40–44]. In 
contrast, FeLV-B was detected in only 25% of multicentric lymphomas, and was not detected in 
myeloproliferative disease or mast cell leukemia. These results confirm the association of FeLV-B 
with thymic lymphoma, but do not indicate a significant role in non-T-cell disease including 
multicentric lymphoma. 
Having described the unique LTR and SU of FeLV-945, a study was undertaken to determine the 
role(s) of these sequence elements in determining the distinctive disease spectrum observed in the 
cohort, i.e., a skew toward non-T-cell disease, particularly a multicentric lymphoma that excludes the 
thymus. For this purpose, recombinant viruses were generated in which either the FeLV-945 LTR 
alone or both the FeLV-945 LTR and SU gene were substituted for homologous sequences in 
FeLV-A/61E to generate the recombinant viruses termed 61E/945L or 61E/945SL, respectively. 
Experimental infection of neonatal kittens with 61E/945L recapitulated the pathogenesis observed with 
FeLV-A/61E, namely thymic lymphoma of T-cell origin, although disease occurred with significantly 
shorter latency. Thus, substitution of the FeLV-945 LTR into FeLV-A/61E did not alter the disease 
outcome but dramatically increased the pace of disease induction. In contrast, substitution of both the 
LTR and SU gene changed the disease outcome entirely, in that infection with 61E/945SL resulted in Viruses 2011, 3                  
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the rapid induction of multicentric lymphoma that involved lymphoid and non-lymphoid organs but 
excluded the thymus. Tumors induced by 61E/945SL were shown by flow cytometry and 
immunohistochemistry to be of B-cell origin. These findings identify the FeLV-945 LTR and SU gene 
as determinants of pathogenesis, indicating that the LTR determines the kinetics of disease induction 
and SU determines the tumorigenic spectrum [37,45]. Recently, an additional recombinant virus has 
been constructed in which only the SU gene of FeLV-945 was substituted into FeLV-A/61E to 
generate a recombinant virus termed 61E/945S. Preliminary findings indicate that infection of neonatal 
kittens with 61E/945S induces thymic lymphoma after prolonged latency, as does FeLV-A/61E. These 
findings support the role of the FeLV-945 LTR as the determinant of more rapid disease induction, and 
indicate that the FeLV-945 LTR and SU must act cooperatively to redirect tumorigenesis to the 
non-T-cell multicentric phenotype [46]. 
Figure 5. Diagrammatic representation of the FeLV-A surface glycoprotein (SU) protein. 
Shown is the 412 amino acid (aa) SU protein indicating approximate positions of the 
functional domains variable region A (VRA), VRB and proline-rich region (PRR). 
Mutation at the indicated residue I186 is implicated in determining receptor-binding 
phenotype via interaction with residue Q110.  
 
 
Considering that the FeLV-945 SU protein enters through the FeLV-A receptor, the possible 
mechanism by which it acts to redirect disease spectrum is not clear. Receptor-binding attributes of 
FeLV-945 SU were examined to explore whether a distinctive phenotype is apparent that may account 
for the unique pathogenesis of FeLV-945 [47]. Using flow cytometric binding assays, virions bearing 
the FeLV-945 envelope protein were observed to bind the cell surface receptor with significantly 
increased affinity, as was soluble FeLV-945 SU protein, when compared to the corresponding virions 
or soluble protein from FeLV-A/61E. This finding was confirmed in several feline cell lines as well as 
in mouse cells engineered to express FeTHTR1. Enhanced binding was observed over a 100-fold range 
of virus concentration, and thus, likely mimics in vivo conditions where amounts of virus or receptor 
may be limiting. We hypothesize that through its increased receptor binding affinity, FeLV-945 SU 
might affect pathogenesis and alter disease outcome by (i) increasing the rate of virus entry and spread 
in vivo, and/or (ii) facilitating entry into a novel target cell with a low receptor density. Studies were Viruses 2011, 3                  
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undertaken to identify which amino acid residues in FeLV-945 SU are responsible for the enhanced 
binding phenotype. Using the crystal structure of the RBD of FeLV-B as a model [48], computational 
molecular modeling was performed to compare the structures of the FeLV-A/61E and FeLV-945 SU 
proteins. The structure of the FeLV-A RBDs did not differ significantly; however, a prominent loop 
located within VRA was predicted from the models of FeLV-A/61E and FeLV-945 that is distinct 
from the known crystal structure of the FeLV-B RBD, and thus may represent the receptor-binding 
surface. Five residues were observed to differ between FeLV-A/61E and FeLV-945 within the loop, 
but reciprocal substitution of these residues did not alter the receptor-binding properties of the parent 
proteins. When larger substitution mutations were made covering the entire SU, only substitution of a 
region of FeLV-945 containing the VRB could confer enhanced binding to FeLV-A/61E SU. 
Mutational analysis of the sequence differences found in the VRB-containing region demonstrated that 
a single residue, valine 186 in FeLV-945 SU, could confer the enhanced receptor-binding phenotype 
when substituted into FeLV-A/61E. Of note is that the substitution, which replaces an isoleucine in 
FeLV-A/61E, is conservative and is located outside consensus VRB. Computational modeling predicts 
a mechanism by which the isoleucine-to-valine change at position 186 contributes to the binding 
phenotype of FeLV-945, i.e., by its influence on a nearby conserved residue, glutamine 110 (Q110). 
The relatively bulky isoleucine side chain at position 186 effectively pushes Q110 into the lower end 
of a large binding cleft, thus narrowing the lower end. The more compact valine side chain, by 
contrast, is predicted to re-orient Q110 such that it does not protrude into the lower end of the binding 
cleft, thus widening the lower end and producing what may represent a better surface conformation for 
interaction with receptor. An inference of this model is that valine 186 acts to enhance the interaction 
of the receptor-binding domain, VRA, with its target [47].  
4. Oncogene Activation in FeLV-Mediated Lymphomas in the Cohort 
As a simple gammaretrovirus, the FeLV genome encodes the genes required for its structure and 
replication,  i.e.,  gag,  pol and env, and no others; thus, unlike complex retroviruses or 
oncogene-containing retroviruses, FeLV encodes no gene to which its malignant potential can be 
directly attributed. It has long been recognized that FeLV, like other simple retroviruses, acts to induce 
neoplasia at least in part by activating cellular oncogenes at the sites of proviral integration. Thus, 
while the LTR acts to direct the expression of viral genes from the integrated provirus, it can act as 
well to promote or enhance transcription of adjacent gene sequences, including potential oncogenes. 
The consequent oncogene activation leads to cell transformation and expansion of a tumor in which the 
causal proviral integration is clonally represented. It is important to appreciate that the integration 
event near an oncogene is not thought to represent targeted integration; rather, it represents a selected 
event in that the cell thereby transformed gives rise to a clonal (or oligoclonal) tumor mass. For this 
reason, when the same genetic locus is observed to be interrupted by proviral integration in multiple 
independent tumors, it is inferred that the commonly interrupted locus encodes an oncogene whose 
activation is relevant to tumor induction [49–51]. Such a locus is then referred to as a common 
insertion site (CIS). FeLV is further known to interact with cellular oncogenes through a distinct 
mechanism, i.e., retroviral transduction, in which the oncogene sequence is incorporated through a 
complex recombination event into the viral genome. Transmission of the oncogene-containing virus Viruses 2011, 3                  
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into a new target cell can then transform the cell directly. Analysis of the natural cohort of 
FeLV-infected animals described here has contributed to our understanding of both mechanisms of 
interaction and to the identification of new CISs and potential oncogenes (Table 1). 
Table 1. Common Integration Sites (CIS) for FeLV as studied through analysis of the 
natural cohort.
a 
CIS Virus  Tumor  Type 
b Gene  Function  Reference
c-Myc  FeLV 
Thymic 
lymphoma 
Controls cell proliferation and 
survival 
[44,52] 
flvi-2 = bmi-1 
FeLV, 
LC-FeLV 
Thymic 
lymphoma  
Controls self-renewal vs. 
differentiation in hematopoiesis 
[44,53,54] 
pim-1  FeLV 
Thymic 
lymphoma  
serine-threonine kinase; survival 
signaling 
[44] 
fit-1  FeLV 
Thymic 
lymphoma  
Unknown [44] 
flvi-1  FeLV-945 
Multicentric 
lymphoma  
Unknown [5,14] 
p101  MoFe2 
Thymic 
lymphoma  
Regulatory subunit of PI3Kγ [55] 
Rasgrp1 MoFe2 
Thymic 
lymphoma  
Ras guanyl releasing protein; cell 
signaling 
[55] 
Jundm2 MoFe2 
Thymic 
lymphoma  
Jun dimerization protein (predicted); 
cell signaling 
[55] 
Ahi-1  MoFe2 
Thymic 
lymphoma  
Abelson helper virus integration site; 
associated with neurologic and 
hematologic disorders 
[55] 
Rras2  MoFe2 
Thymic 
lymphoma  
Ras-related protein; cell signaling  [55] 
a Table 1 summarizes common integration sites studied through analysis of the natural cohort 
and/or through experimental infection with viruses derived from the cohort. Table 1 is not intended 
to represent an inclusive summary of all identified common integration sites for FeLV. 
b Indicated is the tissue in which the common integration was observed. 
4.1. Oncogene Activation in Thymic Lymphomas 
As demonstrated by studies from our laboratory and others over a period of years, FeLV-induced 
thymic lymphomas demonstrate a distinctive pattern of oncogene activation that involves proviral 
integration (or retroviral transduction) of c-myc, bmi-1, pim-1 or fit-1, and frequently involves more 
than one of those loci in the same tumor [44,56]. Our early analysis of the thymic lymphoma of cat 
1110 from the natural cohort demonstrated the unexpected finding of a novel provirus, designated 
LC-FeLV, that contained within it the full coding sequence of the c-myc oncogene. Presumably during 
infection in cat 1110, replicating FeLV had transduced c-myc, replacing the entire pol gene and part of 
the gag and env genes of the virus. The virus was thus rendered replication-defective but presumably 
oncogenic [52,57]. The oncogenic capacity of LC-FeLV was examined in vitro, by infection of 
early-passage feline leukocytes from peripheral blood, spleen, or thymus, or of neonatal feline Viruses 2011, 3                  
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fibroblasts. Unlike other oncogene-containing retroviruses, LC-FeLV did not immortalize these cells 
or alter them morphologically. In contrast, LC-FeLV infection of embryonic feline fibroblasts 
demonstrated partial transformation in that the cells were morphologically altered and demonstrated 
greatly increased proliferative potential, but failed to induce tumors when inoculated into athymic 
mice [58]. Analysis of the tumorigenic potential of LC-FeLV in vivo in cats similarly demonstrated an 
incomplete transforming potential. Specifically, neonatal animals were inoculated with LC-FeLV 
pseudotyped with replication-competent FeLV-A/Glasgow-1 and FeLV-B/Gardner-Arnstein. Of eight 
animals thus inoculated, only three developed thymic lymphoma but did so after a relatively short 
latency of 4–6 months. By comparison, littermates inoculated with helper viruses alone showed no 
signs of malignant disease at the time of necropsy after 11 months of infection [59]. 
The incomplete transforming potential of LC-FeLV in vitro in feline cells, together with the 
inefficient induction of thymic lymphoma in infected animals, suggested that the feline v-myc 
oncogene as represented in LC-FeLV is not sufficient to induce complete transformation, and that 
another genetic event(s) may be required. One possibility considered was that replicating FeLV in the 
infected animals may act as an insertional mutagen to disrupt a second oncogene, whose activation can 
then cooperate with feline v-myc to induce tumors. Analysis of this hypothesis using a strategy of 
transposon tagging demonstrated a locus, designated flvi-2 (feline leukemia virus integration site-2), to 
be commonly interrupted by FeLV proviral insertion in six FeLV-induced thymic lymphomas 
including three induced by infection with LC-FeLV, thus identifying flvi-2 as a CIS and a potential 
collaborator with feline v-myc in tumor induction [53]. The flvi-2 locus was shown to encode 
bmi-1 [60], a polycomb gene family member now known to play an essential role in embryogenesis, 
cell cycle regulation, and the control of self-renewal and differentiation of normal and leukemic stem 
cells [61,62]. The possible role of bmi-1 as a myc-collaborator in the FeLV-mediated induction of 
lymphoma was further examined by screening a large collection of FeLV-positive feline lymphomas 
representing different cohorts and involving different strains of FeLV. In collaboration with several 
colleagues, the coincident involvement of flvi-2 (bmi-1) and myc was examined in a broad geographic 
sampling of naturally and experimentally induced FeLV-positive lymphomas that were heterogeneous 
with respect to the strain of FeLV involved. The results demonstrated FeLV proviral insertions at the 
flvi-2 locus in 7 of 18 thymic lymphomas examined (39%), four of which also exhibited alterations of 
the myc locus. Thus, consistent with our more limited earlier study [53], insertions at flvi-2 were 
detected with approximately equal frequency in the presence and absence of myc involvement. These 
findings supported the concept that bmi-1 can act as a myc collaborator, but that the interaction is not 
required for malignant induction; indeed, we hypothesized from these findings that proviral insertional 
activation of flvi-2 may be an early event in a multistep oncogenic cascade, one possibility for 
completion of which is activation of myc [54]. A larger collaborative study confirmed and extended 
these findings by examining a series of 63 FeLV-positive T-cell lymphomas, including the thymic 
lymphomas from our natural cohort and those experimentally induced by infection with LC-FeLV. The 
tumors were examined for alterations in the c-myc and flvi-2 loci, as well as in fit-1 and pim-1, two 
other loci implicated as myc-collaborators in FeLV-induced disease [63]. The results demonstrated 
retroviral insertion or transduction at c-myc, flvi-2, pim-1 or fit-1 with varying frequencies as high as 
32% in naturally occurring tumors. While interruptions of more than one of those loci within a single Viruses 2011, 3                  
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tumor was detected, the data clearly showed that each locus can contribute to disease induction 
independently, and that cooperative activation between them is not required [44].  
4.2. Oncogene Activation in Multicentric, Non-T-Cell Tumors 
In contrast to thymic lymphomas as described above, the multicentric, non-T-cell tumors in our 
collection demonstrated no involvement of c-myc, flvi-2, fit-1 or pim-1 loci as measured by Southern 
blot analysis for evidence of FeLV proviral insertion or transduction [5,44,54]. Rather, a locus in feline 
DNA termed flvi-1 (feline leukemia virus integration site-1) was identified as a CIS in these tumors, 
shown to be interrupted by FeLV proviral integration in 4 of 11 multicentric lymphomas [5,14]. While 
the coding capacity of flvi-1 remains unknown, the locus is phylogenetically conserved among 
mammals and has been localized to mouse chromosome 2E, adjacent to the known oncogene spi-1 [64].  
Considering its evolutionary conservation and implication as a CIS, flvi-1 is thought to encode an as 
yet unrecognized oncogene whose activity is affected by the nearby integration of the unique 
FeLV-945 LTR. To further explore potential oncogenes whose activity may be altered by adjacent 
integration of the unique LTR, we turned to the large set of lymphomas induced by MoFe2, the 
recombinant virus described above in which the U3 region of the FeLV-945 LTR was substituted for 
that of MoMuLV. While the tumors induced by MoFe2 infection were uniformly thymic lymphomas 
of T-cell origin, they differed from those induced by either parent virus with respect to the pattern of 
oncogene involvement. Specifically, among 44 tumors examined, MoFe2 integration was found 
infrequently (0%–9%) near CISs previously identified for either MoMuLV or FeLV-945 [21,55]. 
Thus, a hunt for new CISs ensued using three different approaches, the results of which identified six 
loci as targets for common MoFe2 insertion. Of these, the loci encoding the genes Rasgrp1, Jundm2, 
Ahi-1, and Rras2 had been previously identified as a CIS in other retroviral models. A CIS was 
identified for the first time that encodes the p101 regulatory subunit of phosphoinositide-3-kinase 
gamma (PI3Kγ), a key regulator of T-lymphocyte proliferation and cytokine production. Identification 
of the p101 gene as a CIS in MoFe2-induced tumors suggested that it may act as an oncogene in the 
induction of T-cell lymphoma in this model. To explore this possibility further, we examined the 
effects of p101 expression and PI3Kγ signaling on T-cell growth and survival. The results provided the 
first evidence that p101 overexpression alone can activate the PI3Kγ pathway by activating the 
catalytic subunit, p110γ, and by sensitizing it to activating signals. Further analysis in human T-cell 
lines demonstrated that moderate levels (but not high levels) of p101 overexpression protected cells 
from apoptosis through a mechanism apparently mediated by Akt phosphorylation [65]. Of the six 
CISs identified in MoFe2-induced tumors, none had previously been reported in tumors induced by 
either parent virus in wild type animals, and two had not previously been reported in any model. Thus, 
substitution of FeLV-945 LTR sequences into MuLV significantly altered the pattern of oncogene 
utilization. These findings indicate that the distinctive sequence and/or structure of the FeLV-945 LTR 
determines its pattern of insertional activation, and demonstrate its utility as a tool for the identification 
of new oncogenes [55,65]. Viruses 2011, 3                  
 
 
1694
5. Conclusions  
FeLV-induced lymphoma is a multistep process that involves complex and interacting genetic 
determinants encoded both by the virus and the host. A collection of diseased tissues from a temporal 
and geographic cohort of naturally infected cats has been extensively examined to identify 
determinants of thymic or multicentric lymphoma in the natural host. The results revealed predominant 
but distinct virus isolates associated with lymphomas of each type. The findings were applied to 
experimental systems, including infections of the natural host with recombinant viruses bearing the 
distinctive features of predominant isolates, and the development of novel MuLV-FeLV recombinant 
viruses such that pathogenesis could be studied in the laboratory mouse. The results of these and other 
studies implicated as major disease determinants the unique FeLV LTR and SU present in the 
predominant natural isolate, and further identified distinct sets of oncogenes activated in each type of 
lymphoma. These studies demonstrate the value and utility of natural clinical material in understanding 
the selective pressures operative in infection of the natural host and the complex interplay of viral and 
host factors that give rise to disease. 
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